An open-label, phase 1a/b study of AB248, a CD8+selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors

被引：0
|
作者：
Buchbinder, Elizabeth I.
Spigel, David R.
Albany, Costantine
Chisamore, Michael
Moynihan, Kelly D.
Liu, Xiaohan
DelNagro, Christopher
Axt, Matt
Pirzkall, Andrea
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT250
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT250
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [22] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [23] An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/ß-catenin pathway inhibitor) plus pembrolizumab in patients with pretreated advanced solid tumors
    Yoshino, Takayuki
    Ikeda, Masafumi
    Finn, Richard S.
    Evans, Thomas R. Jeffry
    Weng, Lidong
    Saito, Kenichi
    Mody, Kalgi
    Tamai, Toshiyuki
    Paoletti, Costanza
    Iwasa, Satoru
    CANCER RESEARCH, 2022, 82 (12)
  • [24] A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Kuboki, Yasutoshi
    Harano, Kenichi
    Koyama, Takafumi
    Kondo, Shunsuke
    Hagiwara, Akiko
    Suzuki, Noriko
    Fujikawa, Ei
    Toyoizumi, Kiichiro
    Mukai, Mayumi
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 376 - 385
  • [25] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [26] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [27] A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors
    Gold, Philip
    Harvey, R. Donald
    Spira, Alexander
    Bazhenova, Lyudmila
    Nemunaitis, John
    Baranda, Joaquina
    Gadgeel, Shirish
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1278 - S1278
  • [28] A Phase 1b Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0941 in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Lolkema, M.
    Leong, S.
    Voest, E.
    Freas, E.
    Shankar, G.
    Brachmann, R. K.
    Moss, R. A.
    Stein, M. N.
    Mergui-Roelvink, M.
    Schellens, J. H. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 111 - 112
  • [29] A PHASE 1/2, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF GI-101 AS A SINGLE AGENT AND IN COMBINATION WITH A PEMBROLIZUMAB, LENVATINIB OR LOCAL RT IN ADVANCED SOLID TUMORS (KEYNOTE-B59)
    Cho, Byoung Chul
    Shin, Sang Joon
    Lee, Jae-Lyun
    Shim, Byoung Yong
    Park, Hyung Soon
    Yun, Nari
    Ham, Mina
    Koh, Young Jun
    Jang, Myoung Ho
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A499 - A499
  • [30] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
12345